4D Molecular Therapeutics, Inc.FDMTNASDAQ
LOADING
|||
EV to Sales: Premium Valuation
Trending higher, above historical average, strong compound growth.
Left:
||||
Enterprise value to sales ratio
Latest
4749.64
↑ 609% above average
Average (7y)
669.65
Historical baseline
Range
High:4749.64
Low:26.16
CAGR
+73.7%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | 4749.64 | +17528.5% |
| 2023 | 26.94 | -87.6% |
| 2022 | 218.05 | +733.6% |
| 2021 | 26.16 | -57.1% |
| 2020 | 60.92 | -58.4% |
| 2019 | 146.48 | +398.5% |
| 2018 | 29.39 | -70.5% |
| 2017 | 99.65 | - |